Palisade Bio, Inc. (PALI)

NASDAQ: PALI · Real-Time Price · USD

0.7556

-0.0207 (-2.67%)

Apr 29, 2025, 4:00 PM EDT - Market closed

Palisade Bio Employees

Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.

Employees

8

Change (1Y)

-1

Growth (1Y)

-11.11%

Revenue / Employee

n/a

Profits / Employee

-$1,804,750

Market Cap

3.32M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	8	-1	-11.11%
Dec 31, 2023	9	-3	-25.00%
Dec 31, 2022	12	-1	-7.69%
Dec 31, 2021	13	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

PALI News

20 days ago - Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewsWire
6 weeks ago - Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewsWire
6 weeks ago - Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewsWire
2 months ago - Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
2 months ago - Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
2 months ago - Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
2 months ago - Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
3 months ago - Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - GlobeNewsWire